Upstream Bio, Inc. (NASDAQ: UPB) does not pay a dividend. As a clinical-stage biotechnology company, it reinvests all available capital directly into research, development, and clinical trial programs, meaning its shares offer zero dividend yield and focus purely on potential capital appreciation.